Similarly, FN improves impaired glucose tolerance through activation of PPAR‐α which inhibits BACE‐1, thereby reducing soluble APPβ and Aβ42 release and enhancing Aβ1‐42 clearance. The gene discussed is PPARA; the disease is Impaired glucose tolerance.